Kishan Mehta
CIK: 0001850520
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Apr 28, 2026BHVN
Biohaven Ltd.
Award(A)DirectStock Options (Right to buy)
68.7K shares- - Mar 17, 2026BHVN
Biohaven Ltd.
Gift(G)Direct17.3K shares- - Mar 17, 2026BHVN
Biohaven Ltd.
Gift(G)Indirect17.3K shares- - Dec 1, 2025BNTC
Benitec Biopharma Inc.
Award(A)DirectOptions (right to buy)
35K shares- - May 5, 2025BHVN
Biohaven Ltd.
Award(A)DirectStock Options (Right to buy)
31.7K shares- - Dec 9, 2024BNTC
Benitec Biopharma Inc.
Award(A)DirectOptions (right to buy)
35K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Apr 28, 2026 |  BHVN Biohaven Ltd. | Award(A) Stock Options (Right to buy) | 68,693 | - | - | Direct |
| Mar 17, 2026 | BHVN Biohaven Ltd. | Gift(G) | 17,342 | - | $0 | Direct |
| Mar 17, 2026 | BHVN Biohaven Ltd. | Gift(G) | 17,342 | - | $0 | Indirect |
| Dec 1, 2025 |  BNTC Benitec Biopharma Inc. | Award(A) Options (right to buy) | 35,000 | - | - | Direct |
| May 5, 2025 | BHVN Biohaven Ltd. | Award(A) Stock Options (Right to buy) | 31,716 | - | - | Direct |
| Dec 9, 2024 | BNTC Benitec Biopharma Inc. | Award(A) Options (right to buy) | 35,000 | - | - | Direct |
1-6 of 6 transactions
About Mehta Kishan
Mehta Kishan (SEC CIK 0001850520) files insider reports with the SEC as Director of Biohaven Ltd. (BHVN) and Director of Benitec Biopharma Inc. (BNTC).
Signal8 holds 5 ownership filings by Mehta Kishan, all Form 4s, filed between Dec 11, 2024 and Apr 30, 2026. Those filings report 6 transactions, from Dec 9, 2024 to Apr 28, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Mehta Kishan's filings is in NEW HAVEN, CT.
Recent filings by Mehta Kishan
- Apr 28, 2026: Grant or award of BHVN derivative securities (Form 4, code A).
- Mar 17, 2026: Gifts of BHVN shares (2 lines, Form 4, code G).
- Dec 1, 2025: Grant or award of BNTC derivative securities (Form 4, code A).
- May 5, 2025: Grant or award of BHVN derivative securities (Form 4, code A).
- Dec 9, 2024: Grant or award of BNTC derivative securities (Form 4, code A).
Other insiders filing for Biohaven Ltd. (BHVN)
- Gentile Kimberly, SVP, Clinical Operations
- Yetimoglu John, Director
- Volles Warren Karl, Chief Legal Officer
- Bailey Gregory, Director
- Heffernan Michael Thomas, Director
- Antonijevic Irina, Director